Houston-based energy tech investor Neal Dikeman writes his observations on Houston's venture capital and startup community's growth — in stark comparison of Silicon Valley's recent evolution. Photo courtesy of the Ion

There's stretch of sleek low rise office buildings in Palo Alto — referred to as Sandhill Road — that has long been the center of Silicon Valley (and the world’s) venture capital sector. An investor friend of mine told me recently that Sandhill Road is a ghost town these days, with the key partners at many of the Silicon Valley venture funds largely working from home or at their second homes.

That’s disappointing if true, but not surprising. Commuting sucks, and this business is a lot more far flung and global than it used to be. The venture capital business is always a wild and fun ride, focused on founders and the next big thing, with constant movement and alliances and partnerships.

I’ve been in these waves since I began investing during the dotcom boom in 2000, making the jump from private equity to venture capital in San Francisco at a fund behind Yellowpages.com and a few others, before co-leading a prior firm I founded in San Francisco doing seed investing and advising funds and investment arms of Macquarie Bank, ConocoPhillips, and Shell. We got in on the ground floor of cleantech and did well. This is my third major VC downcycle – there is always opportunity on both sides, and the more things change, the more they stay the same in venture capital. Hubs matter, because the business is heavily a critical mass of talent and capital business, with a power curve of outcomes. Cutthroat as venture capital and startups are, it is not private equity. You do need partners.

Houston has long lacked a center of gravity at all, let alone in tech. You might try rereading the 2001 Economist headline article “The Blob that Ate East Texas” for some humorous color on that score. But in tech, that’s changing.

Rice University’s Ion Houston innovation district project came out of some of the Greater Houston Partnership work a few years ago on how to get a serious tech hub going (I briefly served on the GHP affiliated Houston Technology Center board for Royal Dutch Shell during that revamp). After a slow start, Ion has begun to fill up with tech startups and bona fide check writing investors to go with the constant barrage of startup programming on its Ion Activation Floor and adjacent Greentown Labs incubation building.

Chevron Technology Ventures opened a guest office on day one on the third floor and Houston private equity and sometime crossover VC investor Ara Partners took early space with its headquarters in the building across the hall from them. Local fund of funds HX Venture Fund, which was created out of that GHP/HTC revamp and also puts on the Venture Houston Conference, moved in on the second floor.

Our fund, Energy Transition Ventures, was the first venture capital fund to move into the Ion when we launched in 2021, is located two doors down from HXVF. My partners and I made the call to make Houston our headquarters over Austin where my partner, Craig Lawrence, is located. He’s a former energy tech and solar executive who learned venture investing leading the successful cleantech effort at Accel Partners in Palo Alto. We are both Texas educated, Bay Area venture capital alums who are doing venture capital in Texas because it’s our home. Our third partner, Q Song, moved from Korea to the US, picking Houston over Austin and our Bay Area office to join us.

Houston was not the obvious choice – it still isn’t – I got nostalgia when driving through Austin and San Francisco in the last week seeing the sheer mass of tech and venture capital names to do business with, but doing things our own way is kind of our brand. We chose the Ion, because well, venture capital and startup life is a participation not a spectator sport, and if Houston was ever going to have a shot at being an investment hub, it needed an actual hub, and founders needed a place to go meet venture capitalists, and that won’t work if venture capitalists all work out of their homes or alone in some energy corridor or downtown high rise.

In our hallway of the Ion, you pass HX Venture Fund, Decarbonization Partners, Energy Transition Ventures, and WaterLens, a water testing startup which spun out of UT many years ago, all next door to each other at one end. And at the other end BP Ventures — with a newly added ExxonMobil venture capital team guest suite adjacent — next to water and energy pipeline corrosion detection software and hardware startup INGU, a Chevron Technology Ventures-backed startup, which is adjacent to one of Houston’s largest venture-backed SaaS companies, Liongard. That’s a half a dozen tech startup founders and a dozen investors across all stages in 125 feet.

I can count approximately 20 other startups in the building now, still heavily skewed to energy. Across the floor, Artemis Energy Partners and Veriten, run respectively by Houston energy fixtures Bobby Tudor and Maynard Holt two of the three Tudor Pickering Holt founders, have their offices, with Schlumberger and hydrogen software startup Velostics which just announced its seed round sandwiched in between. The co-founder of Tierra Climate, a Rice spinout that also just announced its seed round works out of the coworking, and Eigen Controls is building GHG detection equipment around the corner a few feet from an Edtech and medtech startup, and renewable energy services startup Clean Energy Services is headquartered a few feet from the entrance.

Since we moved in, GOOSE Capital, a Houston investment group launched out of Rice at the Rice Alliance Business Competition two decades ago, put its offices in the Ion Activation Floor, and you can quietly find their Managing Director Andrew Nicholson trooping up and down the stairs. BP Ventures then pulled the trigger in 2022 – and moved its US venture capital investing team HQ to the Ion — right down the hallway from us. Chad Bown who manages the US team is sitting in a phone booth 100 feet from me and Chris Spears is listening on pitches as I type this. And this month Decarbonization Partners, the climate growth fund of BlackRock and Temasek, opened its office next door to mine in between us and HX, with three investment professionals, led by David Hayes, formerly with BP Ventures. Aramco Ventures, now led by the former Energy Ventures US head Jim Sledzik, began weekly Friday morning office hours. Jim can often be grabbed for a casual chat on his way between meetings on a regular basis, as can Luis Alcoser or Kemal Anbarci who pop in and out of the Chevron Technology Ventures visiting offices on third floor, with Veriten, which just announced an investment fund, and now Artemis joining recently.

The Houston pool of high quality founders and startups has definitely improved as well – though we still don’t have the quantity or quality of teams needed for a healthy startup market. Blair Garrou from Mercury Fund was part of a recent panel for the Texas Venture Crawl at the Ion along with BP Ventures’ Ion based Grace Chan talking about why Houston, and he remarked that in their earlier funds, Mercury was 5 to 10 percent Houston startups, having to go far afield to fill up even one fund - but his recent fund is closer to 25 percent Houston based, as local team quality has improved.

Houston venture capital is two orders of magnitude smaller than the Bay Area – it’s about like writing an article asking whether Silicon Valley is the emerging Energy Corridor. But it’s nice to have coffee and beers with next door neighbors who are actually investing in, and founders who are actually running, venture backed businesses. Founders are learning that Houston’s venture investment and tech scene has an actual home these days, and is open for business.

------

Neal Dikeman is a venture capitalist and seven-time startup co-founder investing out of Energy Transition Ventures.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.